Braftovi (encorafenib) + cetuximab + chemotherapy as first-line for BRAF V600E metastatic colorectal cancer: what changed after FDA approval
On February 24, 2026, the FDA approved the targeted approach of Braftovi (encorafenib) in combination with cetuximab and fluoropyrimidine-containing chemotherapy as first-line treatment for adult patients with metastatic colorectal cancer harboring a BRAF V600E mutation. This approval was based on the BREAKWATER trial.
Key trial data
BREAKWATER enrolled previously untreated patients with metastatic BRAF V600E-positive colorectal cancer. The primary comparison was between the combination of encorafenib + cetuximab + mFOLFOX6 and standard chemotherapy.
- Median progression-free survival was 12.8 months vs 7.1 months
- Median overall survival was 30.3 months vs 15.1 months
- 47% reduction in risk of progression or death (HR 0.53; p<0.0001)
- 51% reduction in risk of death (HR 0.49; p<0.0001)
- Objective response rate was 61% vs 40% in the control group
In a separate BREAKWATER cohort, the combination of encorafenib + cetuximab + FOLFIRI also demonstrated a high response rate of 64% vs 39%.
Clinical significance
BRAF V600E-positive colorectal cancer has always been considered a clinically more aggressive subgroup. Moving the targeted approach to first-line treatment is highly significant. This means that tumor biology must be taken into account from the very beginning, because it now directly determines the first-line strategy.
The question is no longer just about which chemotherapy regimen to choose, but about how to immediately incorporate a targeted component into the first line of treatment.
Limitations
These data do not apply to all patients with metastatic colorectal cancer. They pertain only to tumors with a confirmed BRAF V600E mutation. Without molecular testing, discussing this regimen is not possible. Furthermore, the combination itself is fairly intensive and requires the organizational capacity to deliver both the targeted and chemotherapy components together.
If you have metastatic colorectal cancer and are choosing first-line treatment
Get a second opinionWhen a second opinion is helpful
- If the metastatic diagnosis is confirmed but BRAF status has not yet been determined
- If BRAF V600E has been found but the first-line treatment plan raises questions
- If you are being offered standard chemotherapy without discussion of the targeted option
- If you need to understand which combination is genuinely right for your specific case
What to prepare for consultation
- Histopathology report
- Molecular testing results, including BRAF status
- CT scans of the chest, abdomen, and pelvis
- Discharge summary with clinical stage and proposed treatment plan
- Blood tests and biochemistry panel
- List of comorbidities and current medications
Frequently asked questions
Is this regimen suitable for all patients with metastatic colorectal cancer?
No. Only for patients with a confirmed BRAF V600E mutation.
Is there an overall survival benefit?
Yes. In BREAKWATER, median overall survival was 30.3 months vs 15.1 months in the control group.
Is molecular profiling necessary before choosing first-line therapy?
Yes. After BREAKWATER, BRAF V600E status becomes critically important at the very start of treatment.